Clinical trials: Hepatobiliary Disorders
Chronic Liver Disease
Comparing Portal Vein Assessment by Intraoperative Doppler and Transesophageal Echocardiography
Liver transplantation is usually associated with hemodynamic instability. TEE allows for a real time monitoring of cardiac structures and has become a standard of care for liver transplant patients.
- Trial name
- NCT06909175
- Testing
- Transesophageal echocardiography
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Associated Fatty Liver Disease
Benefits of Trimetazidine in MASLD Patients
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD
- Trial name
- MASLD (NCT06140953)
- Testing
- Trimetazidine, Conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Fatty Liver
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1).
- Trial name
- NCT07238985
- Testing
- Standard therapy, Cilostazol
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Nonalcoholic Steatohepatitis
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic…
- Trial name
- NCT02442687
- Testing
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily
- Where
- 8 sites in United States
- Volunteers
- 65 people
- Sponsor
- Manal Abdelmalek
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic…
- Trial name
- NCT02781584
- Testing
- SEL, FIR, CILO
- Where
- 13 sites in United States, New Zealand
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Hepatic Impairment
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal…
- Trial name
- NCT07428525
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
Prediabetic State, Non-alcoholic Fatty Liver Disease
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes…
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT02330549
- Testing
- Cenicriviroc 150 mg
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Tobira Therapeutics, Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Type 1 Diabetes
Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk.
- Trial name
- NCT07684248
- Testing
- Intensive lifestyle modification (hypocaloric Mediterranean diet and promotion of physical activity), Butyrate, Intensive lifestyle modification + butyrate
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Thrombelastography, Acute Liver Injury, Acute Decompensation, Platelet
A Prospective Study of Application of Platelet Mapping in Chronic Liver Disease Complicated With ALI and/or AD in China
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of…
- Trial name
- NCT04675125
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome.
- Trial name
- NCT06536933
- Testing
- Abdominal Ultrasound
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Acute Cholecystitis
Functional MRC With Eovist for Acute Cholecystitis
Functional magnetic resonance cholangiography (fMRC) with gadoxetate disodium (Eovist) is an accurate method of diagnosing acute cholecystitis.
- Trial name
- MRC (NCT02100358)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Davis
Non-alcoholic Steatohepatitis (NASH)
Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
Test the efficacy of vitamin D to improve non-alcoholic steatohepatitis with regard to biochemical and histological parameters. Trial with medicinal product
- Trial name
- NCT01571063
- Testing
- Vitamin D3
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single…
- Trial name
- PANASH (NCT03963921)
- Testing
- HepaStem
- Where
- 13 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 23 people
- Sponsor
- Cellaion SA
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis
Spironolactone Therapy In Young Women With NASH
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.
- Trial name
- NCT03576755
- Testing
- Spironolactone 100mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Non-alcoholic Steatohepatitis
First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and…
- Trial name
- NCT05517564
- Testing
- GM-60106
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- JD Bioscience Inc.
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis
Canadian Network for Autoimmune Liver Disease
CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome.
- Conditions
- Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
- Trial name
- CaNAL (NCT03569826)
- Testing
- Observational; no intervention
- Where
- 15 sites in Canada
- Volunteers
- 2,500 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.